Microglial Activation in Inflammatory Bowel Disease

Inflammatory Bowel Diseases Clinical Trial

Official title:

Naturalistic Monitoring of Microglial Activation in Inflammatory Bowel Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03487926
• Other study ID #: 102-2016
• Status: Active, not recruiting
• Start date: September 14, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD and MDE will be subsequently approached to participate in the study.

Description:

Detailed Description: Participants may undergo up to 3 PET Scans : [18F]FEPPA PET (for TSPO) before and 3 to 6 months later and [11C]SL25.1188 PET (for MAO-B) as well as 1 MRI scan. The primary hypothesis is that : 1. The neuroinflammation (TSPO VT) will be increased in PFC, ACC, and insula regions in those with inflammatory bowel disease (IBD) patients compared to healthy people. 2. The neuroinflammation (TSPO VT) in PFC, ACC, and insula regions will be reduced after treatment for IBD. The Secondary Hypothesis: 1. Elevations in neuroinflammation (TSPO VT) will be similar in those with ulcerative colitis and Crohn's disease. 2. Neuroinflammation (TSPO VT) will be greater in IBD with depression than in depression without IBD. 3. Biologics (TNFalpha antibody treatments), and fecal transplantation will be associated with greater reduction in neuroinflammation in brain than Sulfasalazine/5-Aminosalicylates. 4. MAO-B VT will be elevated in in the PFC, ACC, and insula in IBD compared to healthy controls. There will be no alterations to standard care of patients due to participation in the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 135
• Est. completion date: December 31, 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 18 to 65
• aside from IBD groups and common comorbidities of IBD, otherwise good physical health with no current active medical conditions.
• a lifetime diagnosis of IBD verified by medical record, which can include prescription for IBD treatment

Exclusion Criteria:

• no history of neurological illness, excluding migraine
• no use of glucocorticoid antagonists or lithium or medications that bind with affinity higher than 500nM to peripheral benzodiazepine receptors (or TSPO) in the previous two months
• no use of herbal remedies in the previous month that would be expected to influence neuroinflammation
• non-cigarette smoking
• no history of abuse of substances that affect mood and negative urine drug screens for substances of abuse including cotinine (urine drug screen is done at screening and on each PET scan day)
• no history of psychotic symptoms
• not pregnant based on a negative pregnancy test (for women)
• not breastfeeding (for women)
• no recent treatment with electroconvulsive therapy or magnetic seizure therapy in the previous 6 months
• no coagulation disorders, or anticoagulant medication use
• no presence of metal objects or implanted electrical devices in the body that would preclude MRI scanning
• no claustrophobia
• no self-reported history of fainting from blood withdrawals
• size and weight does not exceed capacity of scanner, for which size may vary and weight is 350 lbs
• no history of undergoing a number of PET scans that, including the number of PET scans under this protocol, will bring the total to more than 8 PET scans/lifetime, exceeding permissible limit for subjects participating in research set by our centre's guidelines

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases
• Major Depressive Episode

Intervention

Radiation:
• [18F]FEPPA
up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI

Locations

Country	Name	City	State
Canada	Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health	McMaster University

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.10 — View Citation

Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, Gerhard A, Talbot PS. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. — View Citation

Li H, Sagar AP, Keri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:1-7. doi: 10.1016/j.pnpbp.2017.12.011. — View Citation

Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula	Between group comparison for 3 regions in IBD compared to controls (analysis done concurrently for group effect across 3 regions)	within 3 to 4 weeks after initiation of screening
Primary	change in TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula before and after 3 to 6 months	Change in TSPO VT for three regions (same units for each region)	3 to 6 months
Primary	MAO-B VT in prefrontal cortex, anterior cingulate cortex, insula in IBD compared to controls	Between group comparison for 3 regions in IBD compared to controls	within 3 to 4 weeks after initiation of screening
Secondary	TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between Crohns disease and ulcerative colitis	comparison of TSPO VT in 3 regions between two types of inflammatory bowel disease	within 3 to 4 weeks of initiating screening of subjects
Secondary	TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between IBD with MDE compared to MDE controls	Between group comparison for 3 regions in IBD compared to controls	within 3 to 4 weeks after initiation of screening
Secondary	change in TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between naturalistic treatment with sulfasalazine/5-aminosalicylates versus other interventions like biologics or fecal transplantation	differential change in TSPO VT across 3 regions before and after 6 months in those receiving naturalistic treatment with sulfasalazine/5-aminosalicylates versus other naturalistic treatments of fecal transplantation or biologics	3 to 6 months